相似文献
1
Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both?
Heart. 2006 Jun;92(6):729-34. doi: 10.1136/hrt.2005.066852.
2
[Medical treatments in aortic stenosis: role of statins and angiotensin-converting enzyme inhibitors].
Med Pregl. 2010 Jan-Feb;63(1-2):82-5. doi: 10.2298/mpns1002082d.
3
Targeted therapy to prevent progression of calcific aortic stenosis.
Circulation. 2004 Sep 7;110(10):1180-2. doi: 10.1161/01.CIR.0000140722.85490.EA.
4
[Treatment with statins and angiotensin-converting enzyme inhibitors in degenerative aortic stenosis--an up-date].
Rev Med Chir Soc Med Nat Iasi. 2009 Oct-Dec;113(4):964-74.
5
Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis.
Circulation. 2004 Sep 7;110(10):1291-5. doi: 10.1161/01.CIR.0000140723.15274.53. Epub 2004 Aug 30.
6
Statin therapy of calcific aortic stenosis: hype or hope?
Eur Heart J. 2006 Apr;27(7):773-8. doi: 10.1093/eurheartj/ehi697. Epub 2006 Jan 6.
7
[Research progress on pharmacotherapy of calcific aortic valve disease].
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016 May 25;45(4):432-438. doi: 10.3785/j.issn.1008-9292.2016.07.16.
8
Calcific aortic stenosis and statin therapy: a new insight.
Int J Cardiol. 2009 Jan 9;131(2):275-6; author reply 276-7. doi: 10.1016/j.ijcard.2007.06.125. Epub 2007 Sep 7.
9
Medical therapy for calcific aortic stenosis.
J Cardiovasc Pharmacol Ther. 2012 Jun;17(2):133-8. doi: 10.1177/1074248411416504. Epub 2011 Aug 9.
10
The role of statins in aortic stenosis. Myth or reality?
Rev Port Cardiol. 2007 Jan;26(1):51-62.
引用本文的文献
1
Distinct Genetic Risk Profile in Aortic Stenosis Compared With Coronary Artery Disease.
JAMA Cardiol. 2025 Feb 1;10(2):145-154. doi: 10.1001/jamacardio.2024.3738.
2
Heart surgery over two decades: what we have learned about results and changing risks.
BMC Cardiovasc Disord. 2024 Apr 5;24(1):195. doi: 10.1186/s12872-024-03860-9.
3
End stage renal disease-induced hypercalcemia may promote aortic valve calcification via Annexin VI enrichment of valve interstitial cell derived-matrix vesicles.
J Cell Physiol. 2017 Nov;232(11):2985-2995. doi: 10.1002/jcp.25935. Epub 2017 May 24.
4
Care of patients with apparently asymptomatic severe aortic valve stenosis.
Clin Cardiol. 2012 Dec;35(12):E29-34. doi: 10.1002/clc.22072. Epub 2012 Oct 25.
5
The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality.
J Heart Valve Dis. 2012 May;21(3):337-43.
6
Regular exercise or changing diet does not influence aortic valve disease progression in LDLR deficient mice.
PLoS One. 2012;7(5):e37298. doi: 10.1371/journal.pone.0037298. Epub 2012 May 14.
7
Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.
Int J Angiol. 2008 Summer;17(2):63-70. doi: 10.1055/s-0031-1278283.
8
Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update.
Circulation. 2011 Oct 18;124(16):1783-91. doi: 10.1161/CIRCULATIONAHA.110.006767.
9
Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension.
Int J Clin Pract Suppl. 2010 Nov;64(168):15-22. doi: 10.1111/j.1742-1241.2010.02524.x.
10
Valvular aortic stenosis: a proteomic insight.
Clin Med Insights Cardiol. 2010 Feb 4;4:1-7. doi: 10.4137/cmc.s3884.
本文引用的文献
1
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
Lancet. 2011 Dec 10;378(9808):2013-2020. doi: 10.1016/S0140-6736(11)61125-2. Epub 2011 Nov 22.
2
A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications.
Am Heart J. 2005 Apr;149(4):737-43. doi: 10.1016/j.ahj.2004.06.030.
3
A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
N Engl J Med. 2005 Jun 9;352(23):2389-97. doi: 10.1056/NEJMoa043876.
4
Angiotensin-converting enzyme inhibitors and change in aortic valve calcium.
Arch Intern Med. 2005 Apr 25;165(8):858-62. doi: 10.1001/archinte.165.8.858.
5
Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment?
Ital Heart J. 2005 Feb;6(2):119-24.
6
Induction of local angiotensin II-producing systems in stenotic aortic valves.
J Am Coll Cardiol. 2004 Nov 2;44(9):1859-66. doi: 10.1016/j.jacc.2004.07.054.
7
Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis.
Circulation. 2004 Sep 7;110(10):1291-5. doi: 10.1161/01.CIR.0000140723.15274.53. Epub 2004 Aug 30.
8
Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function.
J Investig Med. 2004 Apr;52(3):185-91. doi: 10.1136/jim-52-03-33.
9
Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS).
Am Heart J. 2004 Apr;147(4):E19. doi: 10.1016/j.ahj.2003.10.017.
10
Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve.
Am J Cardiol. 2003 Jan 1;91(1):97-9. doi: 10.1016/s0002-9149(02)03010-2.
Zotero 插件